Madrigal shares skyrocket on positive NASH treatment study results
December 19, 2022 at 09:36 AM EST
The Conshohocken company expects to seek approval for its treatment of an inflammatory liver disease during the first half of 2023.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|